HeartLight X3
Commercial- Indications
- Atrial fibrillation
Company intelligence / Profile preview
CardioFocus has commercialized the HeartLight Endoscopic Ablation System for pulmonary vein isolation in atrial fibrillation, with over 10,000 patients treated globally. The company’s next-generation pulsed field ablation technologies—including the CE-marked Centauri system and investigational QuickShot catheter—are expanding its portfolio. Human trials for the single-shot PFA balloon HeartLight X4 are expected to begin in 2024. Clinical data support improved precision and safety of their proprietary energy delivery platforms.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CardioFocus.